Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Enfortumab Vedotin Plus Pembro...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer

Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer

Bibliographic Details
Main Authors: Adriana Guarino, Matteo Santoni, Martina Catalano, Giandomenico Roviello
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/11795549251321147
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1177/11795549251321147

Similar Items

  • Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    by: Brigida Anna Maiorano, et al.
    Published: (2023-09-01)
  • Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
    by: Kok Hoe Chan MD, et al.
    Published: (2024-05-01)
  • Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    by: Youwen Zhu, et al.
    Published: (2025-01-01)
  • Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    by: Andong Li, et al.
    Published: (2024-09-01)
  • Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
    by: Blaine Brower, et al.
    Published: (2024-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs